- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04236986
Imaging the Neuroimmune System in PTSD
Imaging the Neuroimmune System in PTSD With PET
In this study, individuals with and without post-traumatic stress disorder (PTSD) will undergo one positron emission tomography (PET) scan using the radiotracer [11C]PBR28, which binds to the 18kDa translocator protein (TSPO). A subset of individuals who complete the first PET [11C]PBR28 scan will be invited to complete an inflammatory challenge and second PET [11C]PBR28 scan. Approximately 3 hours prior to the second [11C]PBR28 PET scan, lipopolysaccharide (LPS; endotoxin) will be administered to evoke a robust neuroimmune response. Subjects will also undergo behavioral and cognitive testing. Vital signs, subjective response, and peripheral biomarker levels will be assayed periodically throughout the experimental session.
Specific aims: 1) Determine if individuals with PTSD exhibit neuroimmune system disruption relative to well-matched comparators at baseline. 2) Determine if individuals with PTSD exhibit a disrupted neuroimmune response after a classical immune stimulus relative to well-matched comparators. 3) Determine if LPS differentially alters cognitive function, subjective response, or physiological markers in individuals with PTSD compared to well-matched comparators.
Hypothesis: Individuals with PTSD will exhibit a suppressed neuroimmune system at baseline and an attenuated neuroimmune response following LPS challenge, relative to matched trauma controls.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jon Anderson
- Phone Number: 2037377074
- Email: jonmikael.anderson@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women, aged 18-55 years
- Subjects with PTSD will have a primary, current diagnosis of PTSD according to DSM-V criteria (i.e., CAPS-5 ascertained diagnosis)
- Able to read and write English and to provide voluntary, written informed consent
Exclusion Criteria:
- Current medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology including COPD, anemia, uncontrolled daily asthma or asthma requiring the use of an inhaler more than 1x/week with an ACT score below 20. [We will not exclude individuals taking SSRIs and TRIs due to high prevalence of use within the PTSD population and due to evidence suggesting no effect of these drug classes on endotoxin response].
- Past or current neurological disorder or disorders affecting the brain including but not limited to multiple sclerosis, history of stroke, brain tumors, traumatic brain injury with loss of consciousness, seizure disorder
- Current or regular use of over-the-counter medication that may affect the immune system
- Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or IUD
- Contraindications to MRI such as claustrophobia or metal in their body
- Individuals who are classified as "low binders" for the rs6971 polymorphism (<10% of the population)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Baseline [11C]PBR28 PET Scan
Subjects will complete a 120-minute baseline [11C]PBR28 PET scan.
|
|
Experimental: Post-LPS [11C]PBR28 PET Scan
Subjects will complete a second120-minute [11C]PBR28 PET scan 3-hours after LPS administration (1.0ng/kg; IV)
|
LPS will be administered intravenously (1.0ng/kg; IV)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline TSPO Availability
Time Frame: Before LPS administration (baseline)
|
Time-activity curves will be extracted from brain regions of interest and analyzed using multilinear analysis-1 (t*=30) incorporating the metabolite-corrected arterial input function to yield [11C]PBR28 total volumes of distribution (VT) across brain regions.
|
Before LPS administration (baseline)
|
Post-LPS TSPO Availability
Time Frame: 3-hours after LPS administration (1.0 ng/kg; IV)
|
Time-activity curves will be extracted from brain regions of interest and analyzed using multilinear analysis-1 (t*=30) incorporating the metabolite-corrected arterial input function to yield [11C]PBR28 total volumes of distribution (VT) across brain regions.
|
3-hours after LPS administration (1.0 ng/kg; IV)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline Visual Attention
Time Frame: Before LPS administration
|
Visual attention: response latency to identify card color (log10(ms); higher ~ worse attention).
|
Before LPS administration
|
Post-LPS Visual Attention
Time Frame: Approximately ~1-hour after LPS administration
|
Visual attention: response latency to identify card color (log10(ms); higher ~ worse attention).
|
Approximately ~1-hour after LPS administration
|
Baseline Visual Learning
Time Frame: Before LPS administration
|
Visual learning: % of correctly identified repeat cards (arcsine(% correct); higher values ~ better learning).
|
Before LPS administration
|
Post-LPS Visual Learning
Time Frame: Approximately ~1-hour after LPS administration
|
Visual learning: % of correctly identified repeat cards (arcsine(% correct); higher values ~ better learning).
|
Approximately ~1-hour after LPS administration
|
Baseline Verbal Memory
Time Frame: Before LPS administration
|
Verbal memory: # of correctly recalled items from a grocery list (3 trials).
Verbal recall: # of correctly recalled items from a grocery list after a delay (1 trial; higher ~ better memory/recall).
|
Before LPS administration
|
Post-LPS Verbal Memory
Time Frame: Approximately ~1-hour after LPS administration
|
Verbal memory: # of correctly recalled items from a grocery list (3 trials).
Verbal recall: # of correctly recalled items from a grocery list after a delay (1 trial; higher ~ better memory/recall).
|
Approximately ~1-hour after LPS administration
|
Baseline Executive Function
Time Frame: Before LPS administration
|
Executive function: number of errors navigating a 'hidden' maze (5 trials; higher ~ worse executive function).
|
Before LPS administration
|
Post-LPS Executive Function
Time Frame: Approximately ~1-hour after LPS administration
|
Executive function: number of errors navigating a 'hidden' maze (5 trials; higher ~ worse executive function).
|
Approximately ~1-hour after LPS administration
|
Baseline Visual-Motor Processing Speed
Time Frame: Before LPS administration
|
Visual-motor processing speed: response latency to detect a card flipped over (log10(ms); higher ~ worse processing speed).
|
Before LPS administration
|
Post-LPS Visual-Motor Processing Speed
Time Frame: Approximately ~1-hour after LPS administration
|
Visual-motor processing speed: response latency to detect a card flipped over (log10(ms); higher ~ worse processing speed).
|
Approximately ~1-hour after LPS administration
|
Baseline Working Memory
Time Frame: Before LPS administration
|
Working memory: % of correctly identified cards that matched the card presented either one- or two-cards previously (arcsine(% correct); higher ~ better working memory).
|
Before LPS administration
|
Post-LPS Working Memory
Time Frame: Approximately ~1-hour after LPS administration
|
Working memory: % of correctly identified cards that matched the card presented either one- or two-cards previously (arcsine(% correct); higher ~ better working memory).
|
Approximately ~1-hour after LPS administration
|
Baseline Social Cognition
Time Frame: Before LPS administration
|
Social cognition: response latency to identify the mismatched facial expression based on its emotional content (ms; log10; higher ~ worse social cognition).
|
Before LPS administration
|
Post-LPS Social Cognition
Time Frame: Approximately ~1-hour after LPS administration
|
Social cognition: response latency to identify the mismatched facial expression based on its emotional content (ms; log10; higher ~ worse social cognition).
|
Approximately ~1-hour after LPS administration
|
Baseline Reward Responsiveness
Time Frame: Before LPS administration
|
Reward responsiveness will be quantified via computerized Probabilistic Reward Task
|
Before LPS administration
|
Post-LPS Reward Responsiveness
Time Frame: Approximately ~2-hour after LPS administration
|
Reward responsiveness will be quantified via computerized Probabilistic Reward Task
|
Approximately ~2-hour after LPS administration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kelly Cosgrove, PhD, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000020347
- 1R01MH110674-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Traumatic Stress Disorder
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
University of ZurichCompletedPost Traumatic Stress Disorder (PTSD) | Complex Post-Traumatic Stress Disorder (CPTSD)Switzerland
-
University of NottinghamNottinghamshire Healthcare NHS Trust; Lincolnshire Partnership NHS Foundation...CompletedDomestic Violence | Trauma, Psychological | Post-Traumatic Stress Disorder in Children | Narrative Exposure Therapy | Post-Traumatic Stress Disorder in Adolescence | Post-Traumatic Stress Disorder ComplexUnited Kingdom
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
-
Direction Centrale du Service de Santé des ArméesRecruitingPost-traumatic Stress DisorderFrance
-
VA Greater Los Angeles Healthcare SystemUniversity of California, Los AngelesRecruitingPost-Traumatic Stress DisorderUnited States
Clinical Trials on Lipopolysaccharide
-
Karolinska InstitutetThe Swedish Research Council; University of California, San Francisco; Swedish... and other collaboratorsCompletedSickness Behavior
-
John SundyTerminated
-
Karolinska InstitutetThe Swedish Research Council; University of California, San Francisco; Swedish... and other collaboratorsCompletedSickness Behavior
-
Patrick Wagner, MD, FACSList Biological Laboratories, IncRecruitingAbdominal Cancer | MalignancyUnited States
-
Radboud University Medical CenterCompletedInnate Immune ResponseNetherlands
-
Radboud University Medical CenterExponential Biotherapies Inc.Completed
-
Radboud University Medical CenterCompleted
-
Karolinska InstitutetDanderyd HospitalCompleted
-
Radboud University Medical CenterCompletedHypoxia | Hyperoxia | NormoxiaNetherlands